Biomass allometry studies routinely assume that regression models can be applied across species and sites, and that goodness of fit of a regression model to its derivation dataset indicates both the relevance of the model to a new dataset and the likely error. Assuming that a model is relevant for a new sample, a prediction interval is a useful error measure for stand mass. Prediction coverage tests whether the model and hence the interval are appropriate in the new sample. Data for three similar shrubby species from four similar sites were combined in various ways to test the impact of varying levels of biodiverse heterogeneity on the performance of the four models most commonly used in published biomass studies. No one model performed consistently well predicting new data, and validation checks were not good indicators of prediction coverage. The highly variable results suggest that the common models might contain insufficient variables. Euclidean distance was used to quantify the relative similarity of samples as a possible means of estimating prediction coverage; it proved unsuccessful with these data.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/bimj.201400070 | DOI Listing |
J Adv Res
December 2024
School of Korean Medicine, Gachon University, Seongnam 13110, Republic of Korea. Electronic address:
Introduction: Network pharmacology has gained significant traction as a tool for identifying the mechanisms and therapeutic effects of herbal medicines. However, despite the usefulness of these approaches, their diversity underscores the critical need for a systematic evaluation to ensure consistency and reliability.
Objectives: We aimed to evaluate the network pharmacological analyses, focusing on identifying the mechanisms and therapeutic effects of herbal medicines.
Proteomes
November 2024
Department of Molecular Biosciences, University of South Florida, Tampa, FL 33620, USA.
As the primary innate immune cells of the brain, microglia play a key role in various homeostatic and disease-related processes. To carry out their numerous functions, microglia adopt a wide range of phenotypic states. The proteomic landscape represents a more accurate molecular representation of these phenotypes; however, microglia present unique challenges for proteomic analysis.
View Article and Find Full Text PDFNucleic Acids Res
December 2024
Department of Pathology & Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
RNA sequencing (RNA-seq) is widely adopted for transcriptome analysis but has inherent biases that hinder the comprehensive detection and quantification of alternative splicing. To address this, we present an efficient targeted RNA-seq method that greatly enriches for splicing-informative junction-spanning reads. Local splicing variation sequencing (LSV-seq) utilizes multiplexed reverse transcription from highly scalable pools of primers anchored near splicing events of interest.
View Article and Find Full Text PDFLiver Transpl
October 2024
Department of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, New York, New York, USA.
Posttransplant diabetes mellitus (PTDM) is associated with significant morbidity and mortality in liver transplant recipients (LTRs). We used the Organ Procurement and Transplantation Network (OPTN) database to compare the incidence of developing PTDM across the United States and develop a risk prediction model for new-onset PTDM using OPTN region as well as donor-related, recipient-related, and transplant-related factors. All US adult, primary, deceased donor, LTRs between January 1, 2007, and December 31, 2016, with no prior history of diabetes noted, were identified.
View Article and Find Full Text PDFJAMA Oncol
December 2024
Mayo Clinic, Departments of Oncology and Molecular Medicine, Rochester, Minnesota.
Importance: Molecular techniques, including next-generation sequencing, genomic copy number profiling, fusion transcript detection, and genomic DNA methylation arrays, are now indispensable tools for the workup of central nervous system (CNS) tumors. Yet there remains a great deal of heterogeneity in using such biomarker testing across institutions and hospital systems. This is in large part because there is a persistent reluctance among third-party payers to cover molecular testing.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!